Condition Lookup
Sub-Category:
Treatment-Related Complications
Number of Conditions: 5
Tumor Lysis Syndrome
Specialty: Oncology
Category: Sarcomas
Sub-category: Treatment-Related Complications
Symptoms:
hyperkalemia; hyperphosphatemia; hypocalcemia; elevated creatinine; nausea; vomiting; fatigue; muscle cramps; seizures
Root Cause:
The rapid release of intracellular contents from dying tumor cells, often after chemotherapy or other treatments, leading to metabolic disturbances.
How it's Diagnosed: videos
Blood tests to measure levels of potassium, phosphate, calcium, creatinine, and uric acid. Clinical presentation and history of recent cancer treatment.
Treatment:
Hydration, medications to control electrolyte imbalances (e.g., sodium bicarbonate, allopurinol), dialysis if necessary, and monitoring in a hospital setting.
Medications:
Allopurinol (a xanthine oxidase inhibitor that reduces uric acid production), Rasburicase (an enzyme that breaks down uric acid), Sodium bicarbonate (to alkalinize urine and prevent uric acid crystallization), Calcium gluconate (to treat hypocalcemia), Potassium binders (to reduce hyperkalemia). These medications are considered urate-lowering agents, electrolyte modifiers, and anti-hyperkalemic agents.
Prevalence:
How common the health condition is within a specific population.
This is a relatively rare condition, occurring in approximately 5-10% of patients receiving chemotherapy for high-grade hematologic cancers like leukemia and lymphoma.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
High tumor burden, especially in hematologic malignancies, rapid tumor cell turnover, and treatments like chemotherapy or radiation therapy.
Prognosis:
The expected outcome or course of the condition over time.
With early detection and treatment, prognosis can be good. However, untreated tumor lysis syndrome can lead to organ failure and death.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Renal failure, cardiac arrhythmias, seizures, and death if not managed promptly.
Chemotherapy-Induced Neuropathy
Specialty: Oncology
Category: Sarcomas
Sub-category: Treatment-Related Complications
Symptoms:
numbness; tingling; pain in hands or feet; weakness; balance problems; sensitivity to touch; loss of reflexes
Root Cause:
Damage to peripheral nerves due to chemotherapy agents, especially those that interfere with microtubules, like taxanes or platinum compounds.
How it's Diagnosed: videos
Clinical evaluation based on symptoms, neurological exam, and sometimes electromyography (EMG) or nerve conduction studies to assess nerve function.
Treatment:
Discontinuation or dose adjustment of the offending chemotherapy agent, use of medications to manage symptoms (e.g., gabapentin, pregabalin), physical therapy for strength and balance, and occupational therapy.
Medications:
Gabapentin (an anticonvulsant used to treat nerve pain), Pregabalin (similar to gabapentin , used to treat neuropathic pain), Duloxetine (a serotonin-norepinephrine reuptake inhibitor for neuropathic pain), and Lidocaine patches (used topically for localized pain). These medications are classified as pain relievers, anticonvulsants, and antidepressants.
Prevalence:
How common the health condition is within a specific population.
This affects up to 40-70% of patients receiving certain chemotherapy drugs, particularly those used in the treatment of breast cancer, lymphoma, and sarcomas.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
High cumulative dose of chemotherapy agents like paclitaxel, cisplatin, or vincristine, pre-existing neuropathy, and age.
Prognosis:
The expected outcome or course of the condition over time.
Neuropathy may improve or resolve after chemotherapy completion, but in some cases, it can be permanent or progressive.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Persistent pain, loss of function, risk of falls, and reduced quality of life.
Radiation-Induced Cancers
Specialty: Oncology
Category: Sarcomas
Sub-category: Treatment-Related Complications
Symptoms:
unexplained weight loss; pain at tumor site; lumps or masses; fatigue
Root Cause:
Genetic mutations or damage caused by radiation therapy, leading to the development of new cancers years or decades after treatment.
How it's Diagnosed: videos
Imaging studies, biopsy, and a thorough medical history of prior radiation therapy.
Treatment:
Treatment depends on the specific type of cancer but may include surgery, chemotherapy, and further radiation therapy.
Medications:
There are no specific medications for radiation-induced cancers; treatment is based on the type of cancer and may include chemotherapy agents (e.g., Doxorubicin , Cyclophosphamide ) and targeted therapies.
Prevalence:
How common the health condition is within a specific population.
Radiation-induced cancers are rare, occurring in approximately 0.5-3% of patients who receive radiation therapy.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
High radiation dose, younger age at the time of radiation exposure, and the area of the body treated.
Prognosis:
The expected outcome or course of the condition over time.
The prognosis depends on the type of radiation-induced cancer and its stage at diagnosis, but generally, these cancers are treatable with conventional cancer therapies.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Secondary cancers, long-term side effects of radiation, and reduced organ function.
Graft-versus-Host Disease (GVHD) after Stem Cell Transplant
Specialty: Oncology
Category: Sarcomas
Sub-category: Treatment-Related Complications
Symptoms:
skin rashes; diarrhea; liver dysfunction; jaundice; dry mouth; fatigue; abdominal pain; fever
Root Cause:
The immune cells from the donor (graft) attack the recipient's tissues (host) after stem cell transplantation.
How it's Diagnosed: videos
Clinical evaluation, biopsy of affected tissue (skin, liver, or gastrointestinal tract), and blood tests for liver enzymes and other markers of inflammation.
Treatment:
Immunosuppressive therapy (e.g., corticosteroids), antithymocyte globulin, and other agents to suppress the immune response.
Medications:
Prednisone (a corticosteroid used to reduce inflammation and suppress the immune system), Mycophenolate mofetil (an immunosuppressive drug), and Tacrolimus (a calcineurin inhibitor). These medications are classified as immunosuppressants.
Prevalence:
How common the health condition is within a specific population.
Around 30-70% of allogeneic stem cell transplant recipients experience some form of GVHD.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Donor-recipient mismatching, younger age of the recipient, and prior history of GVHD.
Prognosis:
The expected outcome or course of the condition over time.
With early treatment, GVHD can often be controlled, but it can lead to chronic disability and even death in severe cases.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Chronic GVHD can affect multiple organs, including the skin, liver, and gastrointestinal tract, leading to long-term disability.
Immunotherapy-Related Adverse Events
Specialty: Oncology
Category: Sarcomas
Sub-category: Treatment-Related Complications
Symptoms:
fatigue; diarrhea; rashes; pneumonitis; colitis; hepatitis; endocrinopathies; arthralgia
Root Cause:
Immune checkpoint inhibitors (e.g., PD-1, PD-L1 inhibitors) inadvertently activate the immune system, leading to attacks on healthy tissues and organs.
How it's Diagnosed: videos
Based on clinical presentation, lab tests for organ function, and imaging to assess organ involvement.
Treatment:
Discontinuation of immunotherapy and corticosteroids (e.g., Prednisone) to reduce immune system activity. In severe cases, additional immunosuppressive agents may be used.
Medications:
Prednisone (used to reduce inflammation and immune response), Mycophenolate mofetil (for severe cases), and Infliximab (a TNF inhibitor used to treat colitis). These are anti-inflammatory and immunosuppressive agents.
Prevalence:
How common the health condition is within a specific population.
Immunotherapy-related adverse events occur in about 30-40% of patients receiving immune checkpoint inhibitors.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Prior autoimmune conditions, combination therapy with immunotherapies, and high-dose treatments.
Prognosis:
The expected outcome or course of the condition over time.
Most immune-related adverse events resolve with early intervention, but severe reactions can result in permanent organ damage.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Organ-specific toxicities (e.g., pneumonitis, hepatitis, colitis), autoimmune disorders, and life-threatening conditions in rare cases.